Scholarlink

<p>The high mortality and morbidity of Head and Neck cancer patients and the toxicity associated to oncological treatments suggest the need for more selective and non-toxic therapies. BNCT (Boron Neutron Capture Therapy) is based on the capture reaction between boron-10, selectively targeted to tumor tissue, and a thermal neutron. In this study, an oral cancer and precancer model was used to study the therapeutic effect and radiotoxicity of BNCT mediated by BPA (boronphenylalanine) [BPA-BNCT] at short and medium-term follow-up. Oligo-Fucoidan, an extract of <i>Laminaria japonica</i> brown seaweed, was evaluated as a potentially beneficial adjunct to BPA-BNCT. Hamsters were chemically cancerized over 8 weeks. Tumor bearing hamsters were assigned to: (CONTROL) cancerized, sham-irradiated group; BPA-BNCT 3&#xa0;Gy absorbed dose to precancerous tissue; BPA-BNCT 3&#xa0;Gy + Oligo-Fucoidan (200&#xa0;mg/kg/day, for 16 days). Neutron irradiation was performed at the RA-3 Nuclear Reactor 3&#xa0;h post administration of BPA (15.5 mg <sup>10</sup>B/kg). Boron biodistribution and microdistribution studies were performed in BPA and BPA + Oligo-Fucoidan groups. Oligo-Fucoidan did not reduce either the incidence of moderate/severe mucositis or reduced the percentage of animals with new tumors in precancerous tissue. Oligo-Fucoidan did enhance BPA-BNCT-induced tumor response at one month (67–94%) and three months after BNCT (42–81%). To understand this effect, boron biodistribution and microdistribution studies were performed. They demonstrated a slight tendency of Oligo-Fucoidan to increase boron concentration in tumors. Oligo-Fucoidan, used in humans and clinical veterinary patients, would be a potentially beneficial adjunct to BNCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of Oligo-Fucoidan as a potentially beneficial adjunct to BNCT in a novel oral cancer and precancer experimental model

  • 期刊论文

  • 发表日期：

    2025年8月19日

查看全文
  • Mónica A. Palmieri,
  • Jessica A. Goldfinger,
  • Paula S. Ramos,
  • Agustina M. Portu,
  • Julia S. Viglietti,
  • Emiliano C.C. Pozzi,
  • Silvia I. Thorp,
  • Paula Curotto,
  • Juan S. Guidobono,
  • Marcela A. Garabalino,
  • Verónica A. Trivillin,
  • Amanda E. Schwint,
  • Andrea Monti Hughes

摘要

The high mortality and morbidity of Head and Neck cancer patients and the toxicity associated to oncological treatments suggest the need for more selective and non-toxic therapies. BNCT (Boron Neutron Capture Therapy) is based on the capture reaction between boron-10, selectively targeted to tumor tissue, and a thermal neutron. In this study, an oral cancer and precancer model was used to study the therapeutic effect and radiotoxicity of BNCT mediated by BPA (boronphenylalanine) [BPA-BNCT] at short and medium-term follow-up. Oligo-Fucoidan, an extract of Laminaria japonica brown seaweed, was evaluated as a potentially beneficial adjunct to BPA-BNCT. Hamsters were chemically cancerized over 8 weeks. Tumor bearing hamsters were assigned to: (CONTROL) cancerized, sham-irradiated group; BPA-BNCT 3 Gy absorbed dose to precancerous tissue; BPA-BNCT 3 Gy + Oligo-Fucoidan (200 mg/kg/day, for 16 days). Neutron irradiation was performed at the RA-3 Nuclear Reactor 3 h post administration of BPA (15.5 mg 10B/kg). Boron biodistribution and microdistribution studies were performed in BPA and BPA + Oligo-Fucoidan groups. Oligo-Fucoidan did not reduce either the incidence of moderate/severe mucositis or reduced the percentage of animals with new tumors in precancerous tissue. Oligo-Fucoidan did enhance BPA-BNCT-induced tumor response at one month (67–94%) and three months after BNCT (42–81%). To understand this effect, boron biodistribution and microdistribution studies were performed. They demonstrated a slight tendency of Oligo-Fucoidan to increase boron concentration in tumors. Oligo-Fucoidan, used in humans and clinical veterinary patients, would be a potentially beneficial adjunct to BNCT.